Abbott Laboratories’ share price retraced back into what many market commentators describe as a ‘buy zone’ following a broad-based sell-off in January. The pullback, driven largely by investor apprehension rather than company-specific deterioration, pushed its valuation multiples below five-year averages. With a current P/E ratio close to 29, dividend yield rising to 2.3% after the most recent increase and net debt representing just 23% of equity, long-term investors view the decline as a chance to accumulate a high-quality, blue-chip healthcare name at an attractive entry point.

In its fourth quarter, Abbott reported revenue of $11.46 billion, up 4.4% year-over-year but approximately 3% below consensus estimates, as Nutrition volumes fell by 8–9% and Diagnostics displayed softer trends. These shortfalls were offset by MedTech growth of roughly 12% and Established Pharmaceuticals up 9%, driving adjusted EPS of $1.50 in line with expectations. The company delivered double-digit bottom-line growth and margin expansion, announced a 7% dividend increase to $0.63 per share, and reaffirmed its Dividend King status. Management issued full-year EPS guidance of $5.55–$5.80 alongside a 6.5%–7.5% sales growth outlook, citing innovation and cost-saving initiatives as buffers against ongoing headwinds.

Twenty-two brokerage firms maintain an average recommendation of Moderate Buy, with 17 buy ratings, 2 strong buys and 3 holds; their average 12-month price target stands near $141. Major banks including Citigroup, Goldman Sachs and RBC have trimmed targets following the earnings report but kept constructive stances. Meanwhile, Abbott’s India affiliate is under government scrutiny for the supply chain of its codeine-based cough syrup, Phensedyl. Regulators discovered that 22 million bottles—valued at about $55 million—were distributed in Uttar Pradesh between April 2024 and March 2025, exceeding medical demand and suggesting diversion into illicit channels. No formal accusations have been leveled at Abbott, but authorities have obtained manufacturing and distribution records during a facility inspection.